AMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMRN is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock has some supportive near-term fundamentals, but the technical trend is still weak and the options setup does not provide a strong bullish confirmation. Given the lack of Intellectia buy signals, the best call is to hold off rather than buy immediately.
The current technical picture is bearish. MACD histogram is negative and expanding, which points to ongoing downside momentum. RSI_6 at 34.76 is near oversold but not yet a strong reversal signal. The moving averages are also bearish, with SMA_200 > SMA_20 > SMA_5, confirming a downtrend. Price at 14.865 is near resistance at 14.943 and still above support at 14.247, with stronger support at 13.552 and 13.123. The short-term pattern data suggests only modest upside probability, not a strong trend reversal.
["Q1 2026 revenue grew 7.3% year over year to $45.1 million, showing top-line progress.", "Operating loss narrowed from $16.8 million to $11.3 million, indicating improving operating efficiency.", "Cash and investments increased to $307.8 million as of March 31, 2026, strengthening the balance sheet.", "Historical analyst expectations were beaten on EPS 100% of the time and revenue 63% of the time over the past two years, which supports credibility.", "Options open interest is heavily call-skewed, which can reflect some bullish market positioning."]
["Q1 2026 GAAP EPS missed expectations by $0.04, showing profitability remains weak.", "Net income fell to -$10.5 million and EPS dropped sharply year over year, indicating earnings deterioration.", "Gross margin declined to 36.84%, which is a significant weakness in operating quality.", "The chart is in a bearish trend with negative MACD momentum and weak moving averages.", "No AI Stock Picker signal and no recent SwingMax signal are present to support an immediate entry.", "Hedge funds and insiders are both neutral, with no notable accumulation signal.", "No recent congress trading data or influential figure buying activity was reported."]
In Q1 2026, Amarin posted revenue of $43.33 million, up 3.12% year over year, which shows modest growth. However, net income was -$10.51 million, EPS was -0.5, and gross margin fell to 36.84%, all of which point to weaker profitability. The latest quarter season is Q1 2026. The company did improve its cash position to $307.8 million and narrowed its operating loss, which is constructive, but the earnings miss and margin decline make the quarter mixed rather than strong.
Recent analyst trend data is not provided in detail, so there is no clear evidence of a broad upgrade or downgrade cycle. Based on the available information, Wall Street appears mixed: the pros include revenue growth, a larger cash balance, and improving operating losses, while the cons are negative EPS, declining gross margin, and weak technical momentum. Overall, analysts would likely view AMRN as a speculative turnaround rather than a strong long-term buy right now.
